Haemacure announces closing of purchase by Angiotech Pharmaceuticals

Haemacure Corporation announces the closing of the purchase by Angiotech Pharmaceuticals, Inc. of substantially all its assets, consisting mainly of its two product candidates and the associated intellectual property and manufacturing plant. The transaction was entered into with authorization from competent courts in Canada and the United States under the Bankruptcy and Insolvency Act and Chapter 11 of the Bankruptcy Code respectively.

As previously announced, Haemacure filed last January a notice of intention to make a proposal to its creditors in Canada and sought court protection in the United States. Haemacure intends to make such proposal no later than April 19, 2010, as authorized by the court. The recovery of any sums by creditors and shareholders is uncertain.

Source:

HAEMACURE CORPORATION

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies